본문 바로가기
KERD
논문KCI 등재

The effect of drug holiday before tooth extraction on the development of medication-related osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates

Çiğdem Karaca|Göknur Topaloğlu-Yasan|Selen Adiloğlu|Ecem Usman
대한구강악안면외과학회 (Korean Association Of Oral And Maxillofacial Surgeons)|2023.04|대한구강악안면외과학회지 (Journal of the Korean Association of Oral and Maxillofacial Surgeons)|제49권 제2호|pp. 68-74|DOI 10.5125/jkaoms.2023.49.2.68

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Tooth extractionBisphosphonateOsteonecrosisBisphosphonate-associated osteonecrosis of the jawCessation of treatment
주제분류치의학

초록

Objectives: Drug holidays are suggested to reduce the formation of osteonecrosis in patients under intravenous (IV) bisphosphonates (BPs) therapy. The objectives of this study are to evaluate the incidence of medication-related osteonecrosis of the jaw (MRONJ) following tooth extraction in cancer patients using IV BP, and to assess the effect of drug holiday on the development of MRONJ. Patients and Methods: A manuel search of the patient folders of Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Hacettepe University was undertaken to identify cancer patients who used IV BPs and had at least one tooth extraction between 2012 and 2022. Patents’ age, sex, systemic condition, the type of BP used, duration of BP used, number of tooth extraction, duration of drug holiday, localization of tooth extraction and incidence of MRONJ were recorded. Results: One hundred nine teeth were removed from 57 jaws in 51 patients. All tooth extractions were performed under perioperative antibiotic prophylaxis and with primary wound closure. The incidence of MRONJ was 5.3%. Stage 1 MRONJ developed in 3 patients (only one had a drug holiday). The median duration of drug holiday was 2 months. No significant difference between the patients with and without a drug holiday and MRONJ development was found (P=0.315). The mean age of patients developed MRONJ was 40.33±8.08 years. A statistically significant difference was found between age and MRONJ development (P=0.002). Conclusion: The effect of a short-term drug holiday on the development of MRONJ may be limited because BPs remain in bone tissue for a long time. Drug holidays should be applied with the approval of an oncologist with other preventive measurements.

Abstract

Objectives: Drug holidays are suggested to reduce the formation of osteonecrosis in patients under intravenous (IV) bisphosphonates (BPs) therapy. The objectives of this study are to evaluate the incidence of medication-related osteonecrosis of the jaw (MRONJ) following tooth extraction in cancer patients using IV BP, and to assess the effect of drug holiday on the development of MRONJ. Patients and Methods: A manuel search of the patient folders of Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Hacettepe University was undertaken to identify cancer patients who used IV BPs and had at least one tooth extraction between 2012 and 2022. Patents’ age, sex, systemic condition, the type of BP used, duration of BP used, number of tooth extraction, duration of drug holiday, localization of tooth extraction and incidence of MRONJ were recorded. Results: One hundred nine teeth were removed from 57 jaws in 51 patients. All tooth extractions were performed under perioperative antibiotic prophylaxis and with primary wound closure. The incidence of MRONJ was 5.3%. Stage 1 MRONJ developed in 3 patients (only one had a drug holiday). The median duration of drug holiday was 2 months. No significant difference between the patients with and without a drug holiday and MRONJ development was found (P=0.315). The mean age of patients developed MRONJ was 40.33±8.08 years. A statistically significant difference was found between age and MRONJ development (P=0.002). Conclusion: The effect of a short-term drug holiday on the development of MRONJ may be limited because BPs remain in bone tissue for a long time. Drug holidays should be applied with the approval of an oncologist with other preventive measurements.

참고문헌 (28)

  1. Berenson JR, "American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma", J Clin Oncol, 20, pp.3719~3736 (2002)[DOI]
  2. Hillner BE, "American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel", J Clin Oncol, 18, pp.1378~1391 (2000)[DOI]
  3. Hillner BE, "American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer", J Clin Oncol, 21, pp.4042~4057 (2003)[DOI]
  4. Watts NB, "Bisphosphonate treatment of osteoporosis", Clin Geriatr Med, 19, pp.395~414 (2003)[DOI]
  5. Anagnostis P, "Bisphosphonate drug holidays--when, why and for how long?", Climacteric, 18(Suppl 2), pp.32~38 (2015)[DOI]
  6. Tanvetyanon T, "Management of the adverse effects associated with intravenous bisphosphonates", Ann Oncol, 17, pp.897~907 (2006)[DOI]
  7. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update", J Oral Maxillofac Surg, 72, pp.1938~1956 (2014)[DOI]
  8. Otto S, "Infection as an important factor in medication-related osteonecrosis of the jaw(MRONJ)", Medicina(Kaunas), 57, pp.463~ (2021)[DOI]
  9. Beth-Tasdogan NH, "Interventions for managing medication-related osteonecrosis of the jaw", Cochrane Database Syst Rev, 7, pp.CD012432~ (2022)[DOI]
  10. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update", J Oral Maxillofac Surg, 80, pp.920~943 (2022)[DOI]
  11. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update", Aust Endod J, 35, pp.119~130 (2009)[DOI]
  12. Jung SY, "Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw", Oral Dis, 25, pp.471~480 (2019)[DOI]
  13. Otsuru M, "Relationship between drug holidays of antiresorptive agents and surgical outcomes in cancer patients with medicationrelated osteonecrosis of the jaw", Int J Environ Res Public Health, 19, pp.4624~ (2022)[DOI]
  14. Marx RE, "Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws : a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)[DOI]
  15. Soutome S, "Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients", Sci Rep, 11, pp.17226~ (2021)[DOI]
  16. Sarin J, "Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis", Oral Dis, 14, pp.277~285 (2008)[DOI]
  17. Zandi M, "Perioperative discontinuation of intravenous bisphosphonate therapy reduces the incidence and severity of bisphosphonate-related osteonecrosis of the jaw : a randomized, controlled, prospective experimental study in rats", J Craniomaxillofac Surg, 43, pp.1823~1828 (2015)[DOI]
  18. Damm DD, "Bisphosphonate-related osteonecrosis of the jaws : a potential alternative to drug holidays", Gen Dent, 61, pp.33~38 (2013)
  19. Wang HL, "Effect of long-term oral bisphosphonates on implant wound healing : literature review and a case report", J Periodontol, 78, pp.584~594 (2007)[DOI]
  20. Otto S, "A drug holiday reduces the frequency and severity of medication-related osteonecrosis of the jaw in a minipig model", J Bone Miner Res, 35, pp.2179~2192 (2020)[DOI]
  21. Hasegawa T, "A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?", Osteoporos Int, 28, pp.2465~2473 (2017)[DOI]
  22. Bodem JP, "Incidence of bisphosphonate-related osteonecrosis of the jaw in high-risk patients undergoing surgical tooth extraction", J Craniomaxillofac Surg, 43, pp.510~514 (2015)[DOI]
  23. Hayashida S, "Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw", J Bone Miner Metab, 38, pp.126~134 (2020)[DOI]
  24. 강상훈, "The effect of bisphosphonate discontinuation on the incidence of postoperative medication-related osteonecrosis of the jaw after tooth extraction", 대한구강악안면외과학회지, 46(1), pp.78~83 (2020), 대한구강악안면외과학회[DOI]
  25. Black DM, "The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis : a randomized second extension to the HORIZONPivotal Fracture Trial(PFT)", J Bone Miner Res, 30, pp.934~944 (2015)[DOI]
  26. Adler RA, "Managing osteoporosis in patients on longterm bisphosphonate treatment : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 31, pp.16~35 (2016)[DOI]
  27. Lee OL, "Bisphosphonate guidelines for treatment and prevention of myeloma bone disease", Intern Med J, 47, pp.938~951 (2017)[DOI]
  28. Van den Wyngaert T, "Bisphosphonates in oncology : rising stars or fallen heroes", Oncologist, 14, pp.181~191 (2009)[DOI]

관련 논문AI추천

The effect of bisphosphonate discontinuation on the incidence of postoperative medication-related osteonecrosis of the jaw after tooth extraction강상훈, 김문기, 박세진대한구강악안면외과학회 · 대한구강악안면외과학회지2020 · 제46권 제1호Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw김윤호, 송승일, 이정근, 이호경대한구강악안면외과학회 · 대한구강악안면외과학회지2014 · 제40권 제5호Clinical investigation of bisphosphonate-related osteonecrosis of the jaws in patients with malignant tumors권대근, Sei-Kyoung Kim대한구강악안면외과학회 · 대한구강악안면외과학회지2012 · 제38권 제3호Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulationBirkan Tatar, Onur Odabaşı, Onur Şahin, Toghrul Aliyev대한구강악안면외과학회 · 대한구강악안면외과학회지2019 · 제45권 제2호Clinical significance of drug cessation on medication-related osteonecrosis of the jaw in patients with osteoporosis서미현, Ju Young Lee, Kezia Rachellea Mustakim, Mi Young Eo, Soung Min Kim대한구강악안면외과학회 · 대한구강악안면외과학회지2023 · 제49권 제2호Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw강몽헌, 김창우, 송인석, 이동건, 전상호대한구강악안면외과학회 · 대한구강악안면외과학회지2018 · 제44권 제5호

이 간행물의 다른 논문 (7건)

Prolotherapy of the temporomandibular joint is denoted as a new health technology in KoreaWon Leepp. 59-60Clinical-pathologic profile of head and neck rhabdomyosarcoma in children: a systematic reviewViviane da Silva Siqueira, Mattheus Augusto Siscotto Tobias, Nelson Leonel Del Hierro Polanco, Beatriz Della Terra Mouco Garrido, Ludimila Lemes Moura, Paulo Sérgio da Silva Santos, Cassia Maria Fischer Rubirapp. 61-67Clinical significance of drug cessation on medication-related osteonecrosis of the jaw in patients with osteoporosisSoung Min Kim, Kezia Rachellea Mustakim, Mi Young Eo, 서미현, Ju Young Leepp. 75-85Management of rare ectopic teeth eruption: case seriesHector Oladapo Olasoji, Ibrahim Kayode Suleiman, Mukhtar Modibbo Ahmad, Olutayo Jamespp. 86-90Effect of a vertical incision on postoperative swelling after an impacted mandibular third molar extraction: two cases with split-mouth designed magnetic resonance imaging analysisJeong-Kui Ku, Sung Hyun Baik, 허종기, 김재영pp. 91-95
원문 보기